Psychosocial Impact of Early Puberty in Girls Aged 6 to 8 Years (PUPSY)

March 25, 2015 updated by: Assistance Publique - Hôpitaux de Paris

Qualitative Assessment of the Psychosocial Impact of Early Puberty in Girls Aged 6 to 8 Years

GnRH agonists are used in the treatment of precocious puberty in order to improve adult height.However,the psychosocial impact of precocious puberty is often used by the clinician at diagnosis to justify treatment, but can not yet be properly assessed. It can not be considered as a rational neither for the indication to treatment, nor to assess its potential efficacy.

The overall objective of this work is to improve the conditions leading to the therapeutic decision and the procedures for monitoring girls with idiopathic central precocious puberty.

Study Overview

Status

Completed

Conditions

Detailed Description

During the day hospital, the diagnostic workup for precocious puberty will be performed and include:

  • A clinical examination with pubertal stage assessment.
  • A GnRH test
  • A Pelvic ultrasound
  • An MRI will be performed later after the results of GnRH test confirming precocious central puberty.

These reviews are conducted as part of usual care and are required to validate the inclusion criteria of patients.

The CBCL questionnaire will be completed by patient's parents and the first semi-structured interview will be conducted by a sociologist assisted by the psychologist, dedicated to the study.

Patient's follow-up will be planned 6 months after inclusion, including similar investigations (except MRI).

Study Type

Observational

Enrollment (Actual)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Paris, France, 75019
        • Assistance Publique - Hôpitaux de Paris

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 years to 8 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

The study will be offered to all children and families who visit in a day hospital in the pediatric endocrinology department of Robert Debré Hospital for further assessment of early puberty.

Description

Inclusion Criteria:

  • 6 to 8 years old girls, with idiopathic central precocious puberty defined as:

    • Onset of clinical signs between 6 and 8 years excluded: breast development (Tanner stage S2 or more), possibly with pubic hair or accelerated growth rate.
    • The GnRH test: LH peak> 5 IU / l during the test.
    • Pelvic ultrasound: uterine length> 34 mm
    • The normality of the hypothalamic-pituitary region assessed by magnetic resonance imaging (MRI).
  • Parental Informed and written consent

Exclusion Criteria:

  • Parents and / or children do not speak French
  • Other chronic disease
  • The child does not benefit of the French social security cover

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Psychosocial characteristics
Time Frame: 1 day
  • The thematic content related to the perception of early puberty, the factors motivating the consultation, the concerns of families and children, psychosocial characteristics of the subjects received in consultation.
  • The thematic content related to the perception of hormone therapy: identifying the knowledge, concerns and expectations regarding the treatment of precocious puberty.
1 day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Child Behavior Checklist
Time Frame: 1 day
Quantitative data on the psychosocial status of patients will be collected as a self-administered questionnaire: the Child Behavior Checklist (CBCL) that is validated.
1 day
Evolution at 6 months
Time Frame: 6 months
Changing views of qualitative and quantitative data will be followed six months after the diagnosis of precocious puberty, with or without treatment.
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Dominique SIMON, MD, PhD, Assistance Publique - Hôpitaux de Paris

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2012

Primary Completion (Actual)

July 1, 2014

Study Completion (Actual)

February 1, 2015

Study Registration Dates

First Submitted

July 25, 2012

First Submitted That Met QC Criteria

September 3, 2012

First Posted (Estimate)

September 6, 2012

Study Record Updates

Last Update Posted (Estimate)

March 26, 2015

Last Update Submitted That Met QC Criteria

March 25, 2015

Last Verified

July 1, 2012

More Information

Terms related to this study

Other Study ID Numbers

  • P111010

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Early Puberty

3
Subscribe